• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Inflection Point Acquisition Corp. V filed SEC Form 8-K: Leadership Update

    1/20/26 5:00:35 PM ET
    $IPEX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IPEX alert in real time by email
    false 0002028355 00-0000000 0002028355 2026-01-20 2026-01-20 0002028355 IPEX:UnitsEachConsistingOfOneClassOrdinaryShareAndOneRightMember 2026-01-20 2026-01-20 0002028355 IPEX:ClassOrdinarySharesParValue0.0001PerShareMember 2026-01-20 2026-01-20 0002028355 IPEX:RightsEachRightEntitlingHolderToReceiveOnefifth15OfOneClassOrdinaryShareUponCompletionOfCompanysInitialBusinessCombinationMember 2026-01-20 2026-01-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(D)
    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): January 20, 2026

     

    INFLECTION POINT ACQUISITION CORP. V

    (Exact name of registrant as specified in its charter)

     

    Cayman Islands   001-42518   N/A
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (I.R.S. Employer
    Identification No.)

     

    167 Madison Ave, Suite 205 #1017
    New York, NY 10016

    (Address of principal executive offices, including zip code)

     

    212-476-6908
    (Registrant’s telephone number, including area code)

     

    Not Applicable
    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Units, each consisting of one Class A ordinary share and one right   IPEXU   The Nasdaq Stock Market LLC
    Class A ordinary shares, par value $0.0001 per share   IPEX   The Nasdaq Stock Market LLC
    Rights, each right entitling the holder to receive one-fifth (1/5) of one Class A ordinary share upon the completion of the Company’s initial business combination   IPEXR   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

     

    On January 20, 2026, the Board of Directors (the “Board”) of Inflection Point Acquisition Corp. V (f/k/a Maywood Acquisition Corp.) (the “Company”) increased the size of the Board from four to five directors and appointed Carolyn Trabuco to serve as a Class II director, with a term expiring at the Company’s second annual meeting of shareholders. Ms. Trabuco was also appointed as a member of the audit committee of the Board.

     

    In connection with her appointment as an independent member of the Board, Ms. Trabuco will receive 20,000 of the previously disclosed 4,481,250 restricted shares of GOWell Energy Technology expected to be issued to the officers and directors of the Company in connection with the consummation of the proposed business combination between the Company and GOWell Technology Limited. As part of her appointment, the Company entered into the Company’s standard form of indemnification agreement with Ms. Trabuco, which is filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on September 12, 2025 and is incorporated herein by reference.

     

    Other than described above, Ms. Trabuco is not a party to any material plan, contract or arrangement with the Company, nor has any other material plan, contract or arrangement to which she is a party been modified as a result of Ms. Trabuco’s appointment described above. There is no arrangement or understanding between Ms. Trabuco and any other person pursuant to which she was selected as an director of the Company and there are no family relationships between Ms. Trabuco and any of the Company’s directors or executive officers. There are no transactions to which the Company is a party and in which Ms. Trabuco has a direct or indirect material interest that would be required to be disclosed under Item 404(a) of Regulation S-K.

     

    1

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: January 20, 2026

     

      INFLECTION POINT ACQUISITION CORP. V
         
      By: /s/ Michael Blitzer
        Name: Michael Blitzer
        Title: Chief Executive Officer

     

    2

    Get the next $IPEX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IPEX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IPEX
    SEC Filings

    View All

    SEC Form 425 filed by Inflection Point Acquisition Corp. V

    425 - Inflection Point Acquisition Corp. V (0002028355) (Subject)

    4/14/26 9:05:21 AM ET
    $IPEX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inflection Point Acquisition Corp. V filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Inflection Point Acquisition Corp. V (0002028355) (Filer)

    4/14/26 9:00:26 AM ET
    $IPEX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 425 filed by Inflection Point Acquisition Corp. V

    425 - Inflection Point Acquisition Corp. V (0002028355) (Subject)

    4/3/26 4:21:11 PM ET
    $IPEX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IPEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GOWell to Host Investor & Analyst Webinar on April 14, 2026

    SINGAPORE and NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- GOWell Technology Limited ("GOWell" or the "Company"), a global one-stop-shop for innovative well logging solutions in the energy sector, will host an Investor & Analyst Webinar on Tuesday, April 14, 2026 at 10:00 a.m. ET. The webinar will include a formal presentation and Q&A session with management. The Company previously announced that it had entered into a Business Combination Agreement with Inflection Point Acquisition Corp. V (NASDAQ:IPEX) ("IPEX"), on October 14, 2025. To register for this webinar, please use the registration link found here. Additionally, for those unable to listen to the live webcast, a recording will be

    3/31/26 6:00:00 PM ET
    $IPEX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GOWell Technology Limited and Inflection Point Acquisition Corp. V Announce Public Filing of Registration Statement on Form F-4 in Connection with Proposed Business Combination

    SINGAPORE and NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- GOWell Technology Limited ("GOWell" or the "Company"), a global one-stop-shop for innovative well logging solutions in the energy sector, and Inflection Point Acquisition Corp. V (NASDAQ:IPEX) ("Inflection Point"), a special purpose acquisition company, have announced the public filing of their joint registration statement on Form F-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") related to their previously announced business combination (the "Business Combination"). The Registration Statement contains a preliminary proxy statement/prospectus of Inflection Point that discloses importan

    3/25/26 6:03:49 PM ET
    $IPEX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GOWell Technology Participates in Advanced Well Integrity Benchmarking Program Coordinated by an Independent Net Zero Organization

    SINGAPORE and NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- GOWell Technology Limited ("GOWell" or the "Company"), a global one-stop-shop for innovative well logging solutions in the energy sector, today announced its participation in a collaborative effort to evaluate next generation well integrity technologies. The evaluation was performed as part of an industry benchmarking program led by an independent Net Zero organization at the NORCE testing facility in Stavanger, Norway. This initiative assessed cutting-edge methods designed to address the industry's most urgent operational and sustainability challenges in well integrity evaluation. As global decommissioning activities accelerate, o

    12/18/25 8:30:00 AM ET
    $IPEX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IPEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Trabuco Carolyn

    3 - Inflection Point Acquisition Corp. V (0002028355) (Issuer)

    1/20/26 5:01:12 PM ET
    $IPEX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Executive Officer Blitzer Michael

    4 - Inflection Point Acquisition Corp. V (0002028355) (Issuer)

    1/5/26 9:41:33 PM ET
    $IPEX
    Biotechnology: Pharmaceutical Preparations
    Health Care